<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123913</url>
  </required_header>
  <id_info>
    <org_study_id>1R01NS095813-01</org_study_id>
    <nct_id>NCT03123913</nct_id>
  </id_info>
  <brief_title>Study of Testosterone and rHGH in FSHD</brief_title>
  <acronym>STARFISH</acronym>
  <official_title>Study of Testosterone and rHGH in FSHD (STARFISH): A Proof-of-Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of combination&#xD;
      therapy with recombinant human growth hormone (rHGH) and testosterone in adult male patients&#xD;
      with facioscapulohumeral muscular dystrophy (FSHD) over 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label study of daily human growth hormone (Genotropin®, 5.0&#xD;
      μg/kg via subcutaneous injection) and testosterone (testosterone enanthate, 140mg via&#xD;
      intramuscular injection every two weeks) for 24 weeks in men with FSHD with a 12 week washout&#xD;
      period. A total of 20 subjects will be enrolled at the University of Rochester Medical Center&#xD;
      in Rochester, NY.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Safety and tolerability are monitored by interval laboratory studies, resting echocardiograms, dual energy x-ray absorptiometry (DEXA) studies, and physical examinations. Patients will report any adverse events through in-person and telephone evaluations as well as on patient diaries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum levels of free and total testosterone, IGF-1, thyroid function, luteinizing hormone and follicle stimulating hormone</measure>
    <time_frame>36 weeks</time_frame>
    <description>Serum levels of free and total testosterone, IGF-1, thyroid function, luteinizing hormone and follicle stimulating hormone will be assessed at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>36 weeks</time_frame>
    <description>Lean body mass will be measured at study visits through dual energy x-ray absorptiometry (DEXA) studies.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ambulation</measure>
    <time_frame>36 weeks</time_frame>
    <description>Ambulation will be assessed as an exploratory measure with the Six Minute Walk Test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Strength</measure>
    <time_frame>36 weeks</time_frame>
    <description>Strength will be assessed as an exploratory measure with manual muscle testing and quantitative muscle testing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary Function</measure>
    <time_frame>36 weeks</time_frame>
    <description>Pulmonary function will be assessed as an exploratory measures with forced vital capacity testing.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient-Reported Disease Burden</measure>
    <time_frame>36 weeks</time_frame>
    <description>Patient-reported disease burden will be assessed as an exploratory measure with the FSHD-Health Index, PROMIS-57, Beck Depression Inventory, Epworth Sleepiness Scale, Fatigue Severity Scale, and International Prostate Symptoms Score.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Facioscapulohumeral Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone Enanthate and Somatropin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Enanthate</intervention_name>
    <description>Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Delatestryl</other_name>
    <other_name>Tesostroval</other_name>
    <other_name>Testro LA</other_name>
    <other_name>Andro LA</other_name>
    <other_name>Durathate</other_name>
    <other_name>Everone</other_name>
    <other_name>Testrin</other_name>
    <other_name>Andropository</other_name>
    <other_name>Testosterone heptanoate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Genotropin</other_name>
    <other_name>Humatrope</other_name>
    <other_name>Norditropin</other_name>
    <other_name>Nutropin</other_name>
    <other_name>Serostim</other_name>
    <other_name>Zorbtive</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A genetically confirmed diagnosis of FSHD (or clinical symptoms suggestive of FSHD&#xD;
             with a first degree relative with genetically confirmed FSHD)&#xD;
&#xD;
          -  Hematocrit of ≤ 50%&#xD;
&#xD;
          -  Prostate-specific antigen ≤ 4.0 ng/ml (or ≤ 3.0 ng/ml if the participant has a&#xD;
             first-degree relative with prostate cancer)&#xD;
&#xD;
          -  Fasting blood glucose &lt;126 mg/dl&#xD;
&#xD;
          -  Able to walk continuously for six minutes (cane, walker, orthoses allowed)&#xD;
&#xD;
          -  Able to independently administer intramuscular and subcutaneous injections (or have a&#xD;
             family member who is capable and willing to administer these injections)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Obesity (BMI&gt;35 kg/m2)&#xD;
&#xD;
          -  Cardiovascular disease (heart failure, coronary artery disease, uncontrolled&#xD;
             hypertension, untreated hypercholesterolemia)&#xD;
&#xD;
          -  Untreated thyroid disease&#xD;
&#xD;
          -  Deep vein thrombosis&#xD;
&#xD;
          -  Untreated severe sleep apnea&#xD;
&#xD;
          -  Past pituitary disease&#xD;
&#xD;
          -  Significant musculoskeletal injury and/or pain that affects walking&#xD;
&#xD;
          -  A systolic blood pressure over 160 or a diastolic pressure over 100&#xD;
&#xD;
          -  Plans to dramatically change exercise habits&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Cancer (other than basal cell skin cancer)&#xD;
&#xD;
          -  Plans to conceive&#xD;
&#xD;
          -  Heavy alcohol use (greater than 50g/day)&#xD;
&#xD;
          -  Current testosterone or HGH use&#xD;
&#xD;
          -  Current use of medications that interfere with the growth hormone or gonadal endocrine&#xD;
             axis.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad R Heatwole, MD, MS-CI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Chad Heatwole</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

